Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect. © 2010 The Author(s).
CITATION STYLE
Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., … Reginster, J. Y. (2010). Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: A consensus document by the Belgian Bone Club. In Osteoporosis International (Vol. 21, pp. 1657–1680). https://doi.org/10.1007/s00198-010-1223-4
Mendeley helps you to discover research relevant for your work.